We are live on ! Find out more

Arcturus Therapeutics

ARCT

Market cap $450M

15.82 USD

+0.26

1.67%

At close Updated Sep 4, 4:00 PM EDT

Pre-market

After hours

15.89

+0.07

0.44%

1 day

1.67%

5 days

5.47%

1 month

154.34%

3 months

96.77%

6 months

108.71%

Year to date

153.12%

1 year

-5.61%

5 years

-72%

10 years

-53.31%

About: Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases. It operates in one business segment, which includes all activities related to the discovery, development, and commercialization of messenger RNA medicines. The company's pipeline includes LUNAR-OTC and LUNAR-CF. Its Vaccine candidates include LUNAR-FLU, KOSTAIVE XBB.1.5, KOSTAIVE, and Others.

Employees: 111

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 35.7%

Neutral 64.3%

Negative 0%

Arcturus Therapeutics to Participate in Upcoming Investor Conferences

SAN DIEGO--(BUSINESS WIRE)---- $ARCT #65Roses--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics, today announced that the Company will participate in the following investor conferences: Wells Fargo 21st Annual Healthcare Conference (Boston) | Fireside Chat September 8, 2026 (2:15 p.m. ET) Citi's 2026 Biopharma Back to School Conference (New York) | Fireside Chat September 9.

Arcturus Therapeutics to Participate in Upcoming Investor Conferences

Zacks Investment Research

Arcturus Therapeutics (ARCT) Just Flashed Golden Cross Signal: Do You Buy?

After reaching an important support level, Arcturus Therapeutics Holdings Inc. (ARCT) could be a good stock pick from a technical perspective. ARCT recently experienced a "golden cross" event, which saw its 50-day simple moving average breaking out above its 200-day simple moving average.

Arcturus Therapeutics (ARCT) Just Flashed Golden Cross Signal: Do You Buy?

Arcturus Therapeutics Eyes Phase III CF Call, OTC Data as Vaccine Funds Pipeline

Arcturus Therapeutics NASDAQ: ARCT is positioning its mRNA platform around two rare-disease programs targeting cystic fibrosis and ornithine transcarbamylase deficiency, while its vaccine business is intended to help support therapeutic development, President and CEO Joseph Payne said during a Canaccord discussion.

Arcturus Therapeutics Eyes Phase III CF Call, OTC Data as Vaccine Funds Pipeline

Arcturus Therapeutics Holdings Inc. (ARCT) Q2 2026 Earnings Call Transcript

Arcturus Therapeutics Holdings Inc. (ARCT) Q2 2026 Earnings Call Transcript

Arcturus Therapeutics Holdings Inc. (ARCT) Q2 2026 Earnings Call Transcript

Zacks Investment Research

Arcturus Therapeutics (ARCT) Reports Q2 Loss, Beats Revenue Estimates

Arcturus Therapeutics (ARCT) came out with a quarterly loss of $0.84 per share versus the Zacks Consensus Estimate of a loss of $1.07. This compares to a loss of $0.34 per share a year ago.

Arcturus Therapeutics (ARCT) Reports Q2 Loss, Beats Revenue Estimates

Arcturus Therapeutics Q2 Earnings Call Highlights

Arcturus Therapeutics NASDAQ: ARCT reported progress across its rare-disease pipeline during the second quarter of 2026, completed enrollment and dosing in its Phase II ornithine transcarbamylase deficiency study, and regained global rights to its KOSTAIVE COVID-19 vaccine and self-amplifying mRNA platform following the end of its collaboration with CSL Seqirus.

Arcturus Therapeutics Q2 Earnings Call Highlights

Arcturus Therapeutics Announces Second Quarter 2026 Financial Results and Pipeline Progress

SAN DIEGO--(BUSINESS WIRE)---- $ARCT #65Roses--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics, today announced its financial results for the quarter ended June 30, 2026, and provided corporate updates. “We are encouraged by the continued progress of our ARCT-032 Phase 2 cystic fibrosis study, with active screening and ongoing enrollment across sites in the United States,.

Arcturus Therapeutics Announces Second Quarter 2026 Financial Results and Pipeline Progress

Arcturus Therapeutics to Report Second Quarter Financial Results and Provide Corporate Update on Aug 6, 2026

SAN DIEGO--(BUSINESS WIRE)---- $ARCT #65Roses--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics, today announced that it will release its financial results for the quarter ended June 30, 2026, after the market close on Thursday, Aug 6th and will also host a conference call and webcast at 4:30 pm Eastern Time on Aug 6, 2026. Arcturus Therapeutics Second Quarter 2026 Earnings.

Arcturus Therapeutics to Report Second Quarter Financial Results and Provide Corporate Update on Aug 6, 2026

Arcturus Therapeutics to Present at the Canaccord Genuity 46th Annual Growth Conference

SAN DIEGO--(BUSINESS WIRE)---- $ARCT #65Roses--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics, today announced that the Company will present at the following investor conference in Boston, Massachusetts: Canaccord Genuity 46th Annual Growth Conference (Fireside Chat) Tuesday, August 11, 2026 (12:00 p.m. ET) Webcast link can be found under Investor Relations/Events section.

Arcturus Therapeutics to Present at the Canaccord Genuity 46th Annual Growth Conference

Arcturus: Now That It's Come This Low, It's Time To Buy And Hold

Arcturus has dropped off enough to make it a net-cash stock - a stock trading for less its current asset value with all liabilities subtracted. A peer group of similar issues that I have rated here on Seeking Alpha has strongly outperformed the S&P 500 even through one of the strongest bull markets in history. This and the combination of a revenue generating asset portfolio and promising pipeline make Arcturus a compelling opportunity.

Arcturus: Now That It's Come This Low, It's Time To Buy And Hold

See News Rankings

Price charts implemented using Lightweight Charts™